To avoid overlaps, the industry is calling for aligning MDR/IVDR with the EU's digital frameworks, pharmaceutical regulations, and clinical trial regulations.

DNA sequencing specialist’s decision to list in London in 2021 was seen as a victory for the market at the time ...

The approval expands the indication for Amvuttra, which now becomes the first and only therapeutic approved by the FDA for ...

Holding Bitcoin could help biotech firms survive the long period of time it takes to bring products to market, says Atai Life ...

Fosamax further defines the obligation of drug manufacturers to present clear, unambiguous, and accurate information to the ...

However, for the Company, 2024 was both a “year of restructuring” amidst challenges and a “year of breakthroughs” with emerging potentials. Although the overall performance is experiencing short-term ...

The Artisan International Small-Mid Fund portfolio outperformed the MSCI ACWI ex USA SMID Index in Q4 of 2024. Click here to ...

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, ...

Beijing's healthcare industry surpassed 1.06 trillion yuan ($146.2 billion) in scale in 2024, marking an 8.7% year-on-year increase and making it the first city in China to reach this milestone, ...

GeekWire Award finalists for Health Innovation of the Year are dominated by ventures that aim to outwit cancer with ...

(Reuters) -Johnson & Johnson said on Friday it plans to invest more than $55 billion over the next four years to build ...

The latest update is out from Shanghai Haohai Biological Technology Co., Ltd. Class H ( ($HK:6826) ). Shanghai Haohai Biological Technology Co., ...